Login
Israel-Hamas Conflict
Benjamin Netanyahu
World Cup
Social Media
Military
Airstrike
Donald Trump
War
Cryptocurrency
Instagram
Soccer
MLB
Immigration
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

J&J's New Triple-Target Cancer Drug Shows Perfect Response Rate in Multiple Myeloma Patients

Summary by stocktitan.net
Novel trispecific antibody demonstrates breakthrough efficacy in treatment-resistant multiple myeloma. See complete trial results and safety data from ASCO 2025.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
pharmaceutical-technology.compharmaceutical-technology.com

ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study - Pharmaceutical Technology

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Read Full Article
stocktitan.netstocktitan.net

J&J's New Triple-Target Cancer Drug Shows Perfect Response Rate in Multiple Myeloma Patients

Novel trispecific antibody demonstrates breakthrough efficacy in treatment-resistant multiple myeloma. See complete trial results and safety data from ASCO 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Tuesday, June 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Johnson & Johnson

Johnson & Johnson

News
For You
SearchBlindspotLocal